Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline Review, H1 2020’, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus (HIV) Infections (AIDS)

– The report reviews pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Human Immunodeficiency Virus (HIV) Infections (AIDS) therapeutics and enlists all their major and minor projects

– The report assesses Human Immunodeficiency Virus (HIV) Infections (AIDS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Human Immunodeficiency Virus (HIV) Infections (AIDS) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2A Pharma AB

AbbVie Inc

Abivax SA

Actinobac Biomed Inc

AdAlta Ltd

Advanced Genetic Systems Inc

Aelix Therapeutics SL

AIM ImmunoTech Inc

Akshaya Bio Inc

AlbaJuna Therapeutics

Altor Bioscience LLC

American Gene Technologies International Inc

Aphios Corp

Apimeds Inc

Atreca Inc

AUM LifeTech Inc

Auritec Pharmaceuticals Inc

Avixgen Inc

B Cell Design SAS

Biological Mimetics Inc

Bionor Holding AS

BioNTech SE

Biosantech SA

Biotron Ltd

Bolder Biotechnology Inc

Brandenburg Antiinfektiva GmbH

Bristol-Myers Squibb Co

BryoLogyx Inc

Bukwang Pharm Co Ltd

Cadila Healthcare Ltd

Califia Bio Inc

Celdara Medical LLC

Celldex Therapeutics Inc

Chiesi Farmaceutici SpA

Chipscreen Biosciences Ltd

Cidara Therapeutics Inc

Clover Biopharmaceuticals

Cocrystal Pharma Inc

Collaborations Pharmaceuticals Inc

Consegna Pharma Inc

CSL Ltd

Curevac AG

Cytocom Inc

Cytodyn Inc

CytRx Corp

DFH Pharma Inc

Diaccurate

E-Vaccines Inc

Emergent BioSolutions Inc

Emmune Inc

Enochian Biosciences Inc

Enzo Biochem Inc

EpiVax Inc

eTheRNA Immunotherapies NV

Evotec SE

Excision BioTherapeutics Inc

ExQor Technologies Inc

FIT Biotech Oy (Inactive)

Fox Chase Chemical Diversity Center Inc

Frontier Biotechnologies Inc

Fujifilm Toyama Chemical Co Ltd

GB Sciences Inc

GeneCure LLC

Genetic Immunity Inc

GeoVax Labs Inc

Gilead Sciences Inc

Globeimmune Inc

Greffex Inc

GT Biopharma Inc

Helocyte Biosciences Inc

Henan Zhenshi Biotechnology Co Ltd

Hepion Pharmaceuticals Inc

Hetero Drugs Ltd

Hoverink Biotechnologies Inc

iCo Therapeutics Inc

ID Pharma Co Ltd

IGXBio Inc

Immune Modulation Inc

Immune Response BioPharma Inc

Immunologik GmbH

Immunotope Inc

ImQuest Life Sciences Inc

Innovare R & D SA De CV

Inovio Pharmaceuticals Inc

Intarcia Therapeutics Inc

Intrucept Biomedicine LLC

InvVax Inc

ISR Immune System Regulation Holding AB

Jericho Sciences LLC

Jiangsu Aidea Pharmaceutical Co Ltd

Johnson & Johnson

Kainos Medicine Inc

Kanglin Biotech Hangzhou Co Ltd

Karyopharm Therapeutics Inc

Kymab Ltd

Laboratory Biodim

Lauren Sciences LLC

Longevity Biotech Inc

Looove Biotechnology Beijing Co Ltd

Lyndra Inc

MacroGenics Inc

Mapp Biopharmaceutical Inc

Merck & Co Inc

Miltenyi Biotec GmbH

Minka Therapeutics SA

Molecular Express Inc

Mologen AG

Mutabilis SA

Mycenax Biotech Inc

Mymetics Corp

NanoViricides Inc

Navigen Inc

NeED Pharma srl

New World Laboratories Inc

NovalGen Ltd

Novodux

Omeros Corp

Oncologie Inc

Oncolys BioPharma Inc

Oncotelic Inc

Oncovir Inc

Orbis Biosciences Inc

Orion Biotechnology Canada Ltd

Osel Inc

OyaGen Inc

Palisades Therapeutics

Pepscan Therapeutics BV

Phoenix Biotechnology Inc

PlantForm Corp

Polyrizon Ltd

Profectus BioSciences Inc

Protheragen Inc

ReceptoPharm Inc

Recombio SL

Repair Biotechnologies Inc

Resverlogix Corp

RetroVirox Inc

Rodos BioTarget GmbH

Samjin Pharm Co Ltd

Sangamo Therapeutics Inc

Savoy Pharmaceuticals Inc

Secura Bio Inc

Serum Institute of India Ltd

Shanghai Pharmaceutical Group Co Ltd

Shionogi & Co Ltd

SignalRx Pharmaceuticals Inc

Sirga Advanced Biopharma Inc

SMET Pharmaceutical Inc

ST Pharm Co Ltd

Staidson BioPharma Inc

Starpharma Holdings Ltd

Sumagen Co Ltd

Sunomix Therapeutics

Susavion Biosciences Inc

Taiga Biotechnologies Inc

TaiMed Biologics Inc

Takara Bio Inc

Takeda Pharmaceutical Co Ltd

Targeted Pharmaceuticals LLC

TechnoVax Inc

TeneoBio Inc

Tetranov International Inc

TGV Laboratories Inc

TheraJect Inc

Theratechnologies Inc

Theravectys SA

Transgene Biotek Ltd

TVAX Biomedical Inc

United Biomedical Inc

Vaccibody AS

Vault Pharma Inc

VG Life Sciences Inc

Vichem Chemie Research Ltd

ViiV Healthcare UK Ltd

Vincogen Corp

Vir Biotechnology Inc

Viramatix Sdn Bhd

Viravaxx AG

Viriom Inc

ViroStatics SRL

ViroXis SAS

Winsantor Inc

XL-protein GmbH

Xyphos Biosciences Inc

Yaso Therapeutics Inc

Yisheng Biopharma Co Ltd

Zata Pharmaceuticals Inc

Zion Medical

Table of Contents

Table of Contents

Introduction

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Overview

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Development

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Assessment

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Companies Involved in Therapeutics Development

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Drug Profiles

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by 2A Pharma AB, H1 2020

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by AbbVie Inc, H1 2020

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Abivax SA, H1 2020

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by Actinobac Biomed Inc, H1 2020

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline by AdAlta Ltd, H1 2020

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects, H1 2020

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports